Look for Drugs and Conditions

Representative Image

Tokyo University Scientists Discover New Drug Target for Osteoporosis

Tokyo University's groundbreaking study has identified a potential pharmaceutical target that could significantly alter the treatment of osteoporosis. This severe disorder weakens bones and increases their risk of breaking for millions of people worldwide, the majority of whom are old. Researchers uncovered a new gene critical for bone formation. This might lead to more effective osteoporosis therapies and care. Their results has given patients new hope and considerably advanced our understanding of bone health.

Teriparatide, a parathyroid hormone-derived drug, currently improves bone development in osteoporosis patients. However, it also produces osteoclasts, which destroy bones. The reciprocal effect may diminish drug efficacy. It is yet unclear how PTH changes bone cells.

Professor Tadayoshi Hayata and Ms. Chisato Sampei of the Tokyo University of Science studied the impact of PTH on genes in osteoblasts, which are the cells that build bones. According to Hayata, osteoporosis affects around 12.8 million people in Japan, or one in every ten, and severely degrades their quality of life. "Knowing the complete action of teriparatide is essential because it promotes bone breakdown as well as bone building."

Osteoporosis sufferers' bones are fragile and prone to fracture. Osteoporosis causes 8.9 million bone fractures each year. It implies that one person breaks a bone every three seconds. The elderly are particularly susceptible since they typically require long-term care. Working osteoporosis medications become increasingly necessary as people live longer lives, working osteoporosis medications are becoming increasingly necessary.

Teriparatide treatment of mouse bone cells resulted in changes in gene activity. They discovered that PTH might activate a new gene known as Gprc5a. Researchers have previously studied a protein this gene generates, despite its unrelatedness to body cell formation.

PTH is known to stimulate certain cell signals. These signals, the researchers discovered, may also activate Gprc5a. They observed that Gprc5a quickly reacts to PTH and affects bone cell proliferation and development.

When the researchers lowered the amount of Gprc5a, the bone cells formed and matured faster. Gprc5a also interacts with another protein that stimulates bone growth, scientists discovered. This suggests that Gprc5a alters this protein's action, thereby delaying bone formation.

"Our findings suggest that Gprc5a may prevent teriparatide from forming bones," Prof. Hayata stated. In those who don't respond well to teriparatide, inhibiting Gprc5a may help. Our goal with this study is to improve people with osteoporosis' quality of life and well-being.

This discovery might lead to the development of new osteoporosis medications that better balance bone creation and breakdown. This gives hope to millions of people who are suffering from this agonizing illness.

Be first to post your comments

Post your comment

Related Articles

Ad 5